在CML治疗中的新篇章:阿司明尼布的前景
Maimoona Akhtar1, Zoha Jamal1, Sanila Mughal2
1Department of Medicine, Karachi Medical and Dental College, Karachi, Pakistan.
Annals of medicine and surgery (2012)
|April 11, 2025
概括
阿西米尼布是一种新的FDA批准的慢性髓性白血病 (CML) 治疗方法,其向的是myristoyl口袋. 这种STAMP抑制剂显示出比传统的氨酸激酶抑制剂 (TKI) 更高的疗效和更好的安全性.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性髓性白血病 (CML) 经常用氨酸激酶抑制剂 (TKIs) 治疗.
- 对TKI的耐药性是一个重大的临床挑战.
- 需要新的治疗策略来改善CML治疗结果.
研究的目的:
- 为了评估阿斯基米尼布的疗效和安全性,一个STAMP抑制剂,在CML治疗.
- 为了比较阿西米尼布的性能与现有的技术知识.
- 探索阿西米尼布在各种CML治疗环境中的潜力.
主要方法:
- 在ASC4FIRST临床试验中,研究了阿西米尼布的疗效和安全性.
- 阿西米尼布向BCR-ABL1蛋白的myristoyl口袋.
- 与现有的TKI疗法进行了比较分析.
主要成果:
- 与现有的TKIs相比,阿西米尼布显示出更高的分子响应率.
- 该药物显示出良好的安全性,并减少了严重的副作用.
- 观察到血管和肺部不良事件的风险较低.
结论:
- 阿西米尼布为克服CML中TKI抵抗提供了一种新的机制.
- 它代表了CML治疗的重大进步,改善了耐受性和结果.
- 关于长期耐用性,安全性和组合疗法的进一步研究正在进行中.
相关概念视频
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
107
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
107


